When ImClone knew

In testimony to Congress on Thursday, IMCL President and CEO Harlan Waksal acknowledged that he, his brother Samuel Waksal, and other IMCL executives knew in mid-December that FDA was seriously considering rejecting the BLA for the company's Erbitux antibody to treat colorectal cancer, and that IMCL had detailed knowledge of FDA's decision to issue a

Read the full 550 word article

How to gain access

Continue reading with a
two-week free trial.